Venom Spin-off From Insomniac Confirmed In Latest Leaks

Expert Verified By

Venom: Lethal Protector Coming In 2025!

Story Highlights
  • The next game from Insomniac was expected to be Marvel’s Wolverine. 
  • According to new leaks, a Venom spin-off is coming from the studio in 2025.
  • The game will lead up to Spider-Man 3’s story, and it will offer 8-10 hours of content for $49.99.

Marvel’s Spider-Man 2 became famous for many defining characteristics. With over 2.5 million sales on day one, Insomniac proved its latest superhero adventure was no slouch.

The studio’s portrayal of Venom was remarkable and became one of the aforementioned characteristics. According to leaks, fans are in for more time with this villain since Insomniac Games is working on a standalone spin-off for the character.

Why it matters: Marvel’s Spider-Man 2 spurred demand for a Venom spin-off. The studio was also quick to respond, claiming that it would not disappoint fans if there was enough demand.

Marvel's Spider-Man 2

A Reddit post details the complete list of leaks from Insomniac. The studio was victim to a ransomware attack, confirming projects like Marvel’s Spider-Man 3 and a new X-Men game.

Among the leaks, Insomniac’s roadmap confirms the standalone Venom game. Titled Venom: Lethal Protector, this will be the developer’s next project, due for release in 2025.

The game picks up after Marvel’s Spider-Man 2 with a completely new storyline and sets up Marvel’s Spider-Man 3. According to leaked slides, it includes more than just Venom, allowing players to switch between this villain and the Spider-Heroes.

The studio seems to have taken inspiration from Marvel’s Spider-Man: Miles Morales for this standalone entry. Therefore, it will last around 8-10 hours, offering 12 missions and 3 event bosses.

Adding optional content, some quests, a few challenges, and more, Venom: Lethal Protector will offer enough content for its $49.99 asking price.

It takes around 15-17 hours to complete Marvel’s Spider-Man 2.

Compared to its $70 price, the Venom spin-off appears to justify its cost. A leaked roadmap from the same ransomware attack confirms Insomniac is targeting a Q2 2025 launch, making it the studio’s very next project.

While everyone speculated that Marvel’s Wolverine would arrive by 2025, Insomniac seems to have different plans. This title will be released in 2026 after the spin-off based on Venom.

By 2025, Marvel’s Spider-Man 2 will go on sale and likely reach a much bigger audience, setting the stage for Venom: Lethal Protector. This will be a nice change of pace for Insomniac and audiences since they will abandon the traditional role of a superhero for a while.

Was our article helpful? 👨‍💻

Thank you! Please share your positive feedback. 🔋

How could we improve this post? Please Help us. 😔

Gear Up For Latest News

Get exclusive gaming & tech news before it drops. Sign up today!

Join Our Community

Still having issues? Join the Tech4Gamers Forum for expert help and community support!

Latest News

Join Our Community

104,000FansLike
32,122FollowersFollow

Trending

FromSoftware’s The Duskbloods To Receive Player Impressions Next Week

The Duskbloods previews are said to be on their way ahead of the game's official closed network test in August.

CDPR’s The Witcher Multiplayer Spin-off Loses 18 Devs Amid Layoffs

Project Sirius, The Witcher multiplayer spin-off, may be in trouble following a new round of job cuts within the team.

Phantom Blade Zero Shoots Up To #1 Spot on Steam Best-Sellers As Pre-orders Go Live

With Phantom Blade Zero now available to pre-order, the game has already become Steam's best-selling game in no time.

Sony Reportedly Working On Original Character IPs To Compete With Nintendo And Sega

A new report reveals that Sony is working on multiple character IPs in hopes of growing one into a global evergreen mascot by 2030.

PS5 Suffers From Overheating After Liquid Metal Damages Heatsink

Another case of PS5 overheating due to liquid metal problems has surfaced online, with the coolant leaving a huge gap on the APU.